Which has higher earnings and valuation, IVVD or MDXG?

MiMedx Group has higher revenue and earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invivyd $53.43M 3.79 -$52.49M -$0.31 N/A MiMedx Group $418.63M 1.46 $48.58M $0.04 104.88

Is IVVD or MDXG more profitable?

MiMedx Group has a net margin of 1.76% compared to Invivyd's net margin of -138.90%. MiMedx Group's return on equity of 12.09% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -138.90% -53.48% -41.56% MiMedx Group 1.76% 12.09% 9.22%

Do analysts rate AVTE or IVVD?

Invivyd has a consensus price target of $8.00, indicating a potential upside of 1,062.79%. Given Invivyd's stronger consensus rating and higher possible upside, analysts clearly believe Invivyd is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Invivyd 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is IVVD or NVCT more profitable?

Nuvectis Pharma has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Invivyd's return on equity of -53.48% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -138.90% -53.48% -41.56% Nuvectis Pharma N/A -184.25% -105.24%

Does the media refer more to IVVD or NVCT?

In the previous week, Invivyd had 1 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Invivyd and 4 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.89 beat Invivyd's score of -0.62 indicating that Nuvectis Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Nuvectis Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MPLT or IVVD?

In the previous week, Maplight Therapeutics had 3 more articles in the media than Invivyd. MarketBeat recorded 8 mentions for Maplight Therapeutics and 5 mentions for Invivyd. Maplight Therapeutics' average media sentiment score of 0.80 beat Invivyd's score of -0.62 indicating that Maplight Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invivyd 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Which has higher earnings and valuation, IVVD or ALT?

Invivyd has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invivyd $53.43M 3.79 -$52.49M -$0.31 N/A Altimmune $40K 14,172.00 -$88.09M -$0.93 N/A

Is IVVD or ALT more profitable?

Invivyd has a net margin of -138.90% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -39.64% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -138.90% -53.48% -41.56% Altimmune -214,860.98% -39.64% -33.01%

Does the media refer more to IVVD or ALT?

In the previous week, Altimmune had 6 more articles in the media than Invivyd. MarketBeat recorded 11 mentions for Altimmune and 5 mentions for Invivyd. Altimmune's average media sentiment score of 0.24 beat Invivyd's score of -0.62 indicating that Altimmune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Invivyd (IVVD) Competitors

$0.69 +0.00 (+0.34%)

As of 12:45 PM Eastern

Compare

IVVD vs. MDXG, AVTE, NVCT, MPLT, and ALT

Should you buy Invivyd stock or one of its competitors? Invivyd's main competitors and comparable companies include MiMedx Group (MDXG), Aerovate Therapeutics (AVTE), Nuvectis Pharma (NVCT), Maplight Therapeutics (MPLT), and Altimmune (ALT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Invivyd compare to MiMedx Group?

Invivyd (NASDAQ:IVVD) and MiMedx Group (NASDAQ:MDXG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Invivyd has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

MiMedx Group has a net margin of 1.76% compared to Invivyd's net margin of -138.90%. MiMedx Group's return on equity of 12.09% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-138.90%	-53.48%	-41.56%
MiMedx Group	1.76%	12.09%	9.22%

Invivyd currently has a consensus target price of $8.00, indicating a potential upside of 1,062.79%. MiMedx Group has a consensus target price of $8.50, indicating a potential upside of 102.62%. Given Invivyd's higher probable upside, research analysts clearly believe Invivyd is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Invivyd had 4 more articles in the media than MiMedx Group. MarketBeat recorded 5 mentions for Invivyd and 1 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.89 beat Invivyd's score of -0.62 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Invivyd	Negative
MiMedx Group	Very Positive

MiMedx Group has higher revenue and earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	3.79	-$52.49M	-$0.31	N/A
MiMedx Group	$418.63M	1.46	$48.58M	$0.04	104.88

70.4% of Invivyd shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 12.3% of Invivyd shares are held by insiders. Comparatively, 2.5% of MiMedx Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

MiMedx Group beats Invivyd on 12 of the 16 factors compared between the two stocks.

How does Invivyd compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Invivyd (NASDAQ:IVVD) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Aerovate Therapeutics has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Invivyd's return on equity of -53.48% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Invivyd	-138.90%	-53.48%	-41.56%

Invivyd has a consensus price target of $8.00, indicating a potential upside of 1,062.79%. Given Invivyd's stronger consensus rating and higher possible upside, analysts clearly believe Invivyd is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Invivyd had 5 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 5 mentions for Invivyd and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.00 beat Invivyd's score of -0.62 indicating that Aerovate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Invivyd	Negative

70.4% of Invivyd shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by insiders. Comparatively, 12.3% of Invivyd shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market.

Invivyd has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Invivyd	$53.43M	3.79	-$52.49M	-$0.31	N/A

Summary

Invivyd beats Aerovate Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Invivyd compare to Nuvectis Pharma?

Invivyd (NASDAQ:IVVD) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

70.4% of Invivyd shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 12.3% of Invivyd shares are owned by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Invivyd presently has a consensus price target of $8.00, indicating a potential upside of 1,062.79%. Nuvectis Pharma has a consensus price target of $35.00, indicating a potential upside of 82.09%. Given Invivyd's higher probable upside, equities research analysts clearly believe Invivyd is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Nuvectis Pharma has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Invivyd's return on equity of -53.48% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-138.90%	-53.48%	-41.56%
Nuvectis Pharma	N/A	-184.25%	-105.24%

In the previous week, Invivyd had 1 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Invivyd and 4 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.89 beat Invivyd's score of -0.62 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Nuvectis Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Invivyd has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market.

Nuvectis Pharma has lower revenue, but higher earnings than Invivyd. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	3.79	-$52.49M	-$0.31	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Summary

Invivyd beats Nuvectis Pharma on 9 of the 14 factors compared between the two stocks.

How does Invivyd compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Invivyd (NASDAQ:IVVD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Maplight Therapeutics currently has a consensus price target of $29.67, indicating a potential upside of 155.53%. Invivyd has a consensus price target of $8.00, indicating a potential upside of 1,062.79%. Given Invivyd's higher possible upside, analysts plainly believe Invivyd is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Maplight Therapeutics has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Maplight Therapeutics' return on equity of 0.00% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Invivyd	-138.90%	-53.48%	-41.56%

In the previous week, Maplight Therapeutics had 3 more articles in the media than Invivyd. MarketBeat recorded 8 mentions for Maplight Therapeutics and 5 mentions for Invivyd. Maplight Therapeutics' average media sentiment score of 0.80 beat Invivyd's score of -0.62 indicating that Maplight Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Invivyd	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Invivyd has higher revenue and earnings than Maplight Therapeutics. Invivyd is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Invivyd	$53.43M	3.79	-$52.49M	-$0.31	N/A

70.4% of Invivyd shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by insiders. Comparatively, 12.3% of Invivyd shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Maplight Therapeutics beats Invivyd on 9 of the 15 factors compared between the two stocks.

How does Invivyd compare to Altimmune?

Invivyd (NASDAQ:IVVD) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

In the previous week, Altimmune had 6 more articles in the media than Invivyd. MarketBeat recorded 11 mentions for Altimmune and 5 mentions for Invivyd. Altimmune's average media sentiment score of 0.24 beat Invivyd's score of -0.62 indicating that Altimmune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Invivyd has a net margin of -138.90% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -39.64% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-138.90%	-53.48%	-41.56%
Altimmune	-214,860.98%	-39.64%	-33.01%

Invivyd has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	3.79	-$52.49M	-$0.31	N/A
Altimmune	$40K	14,172.00	-$88.09M	-$0.93	N/A

Invivyd has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Invivyd presently has a consensus price target of $8.00, indicating a potential upside of 1,062.79%. Altimmune has a consensus price target of $14.33, indicating a potential upside of 391.71%. Given Invivyd's higher probable upside, equities analysts clearly believe Invivyd is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Altimmune	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

70.4% of Invivyd shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 12.3% of Invivyd shares are owned by company insiders. Comparatively, 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Invivyd and Altimmune tied by winning 8 of the 16 factors compared between the two stocks.

Get Invivyd News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IVVD vs. The Competition

Export

Metric	Invivyd	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$202.69M	$3.70B	$6.98B	$13.03B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-2.22	10.37	269.56	25.24
Price / Sales	3.79	1,289.70	596.34	100.74
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	0.66	17.36	13.02	6.32
Net Income	-$52.49M	-$13.32M	$3.45B	$347.92M
7 Day Performance	-7.03%	0.73%	0.69%	0.91%
1 Month Performance	-14.09%	0.52%	1.32%	0.89%
1 Year Performance	-13.92%	54.37%	66.86%	20.28%

Invivyd Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IVVD Invivyd	3.2233 of 5 stars	$0.69 +0.3%	$8.00 +1,062.8%	-13.5%	$202.69M	$53.43M	N/A	100	News Coverage Earnings Report
MDXG MiMedx Group	2.979 of 5 stars	$4.27 +3.4%	$8.50 +99.1%	-42.2%	$601.99M	$418.63M	106.78	870
AVTE Aerovate Therapeutics	N/A	$19.75 -1.3%	N/A	+214.1%	$572.45M	N/A	N/A	20	High Trading Volume
NVCT Nuvectis Pharma	3.648 of 5 stars	$21.60 +0.4%	$35.00 +62.0%	+201.9%	$570.83M	N/A	N/A	8	Gap Up
MPLT Maplight Therapeutics	4.1763 of 5 stars	$12.55 -3.6%	$34.42 +174.2%	N/A	$554.89M	N/A	N/A	109	Earnings Report Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IVVD) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Invivyd (IVVD) Competitors

IVVD vs. MDXG, AVTE, NVCT, MPLT, and ALT

How does Invivyd compare to MiMedx Group?

Summary

How does Invivyd compare to Aerovate Therapeutics?

Summary

How does Invivyd compare to Nuvectis Pharma?

Summary

How does Invivyd compare to Maplight Therapeutics?

Summary

How does Invivyd compare to Altimmune?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD vs. The Competition

Invivyd Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Invivyd (IVVD) Competitors

IVVD vs. MDXG, AVTE, NVCT, MPLT, and ALT

How does Invivyd compare to MiMedx Group?

Which has more volatility & risk, IVVD or MDXG?

Is IVVD or MDXG more profitable?

Do analysts recommend IVVD or MDXG?

Does the media refer more to IVVD or MDXG?

Which has higher earnings and valuation, IVVD or MDXG?

Do institutionals and insiders believe in IVVD or MDXG?

Summary

How does Invivyd compare to Aerovate Therapeutics?

Is AVTE or IVVD more profitable?

Do analysts rate AVTE or IVVD?

Does the media favor AVTE or IVVD?

Do insiders & institutionals believe in AVTE or IVVD?

Which has more risk and volatility, AVTE or IVVD?

Which has preferable earnings and valuation, AVTE or IVVD?

Summary

How does Invivyd compare to Nuvectis Pharma?

Do insiders and institutionals believe in IVVD or NVCT?

Do analysts recommend IVVD or NVCT?

Is IVVD or NVCT more profitable?

Does the media refer more to IVVD or NVCT?

Which has more volatility & risk, IVVD or NVCT?

Which has better valuation & earnings, IVVD or NVCT?

Summary

How does Invivyd compare to Maplight Therapeutics?

Do analysts prefer MPLT or IVVD?

Is MPLT or IVVD more profitable?

Does the media prefer MPLT or IVVD?

Which has preferable valuation & earnings, MPLT or IVVD?

Do insiders and institutionals hold more shares of MPLT or IVVD?

Summary

How does Invivyd compare to Altimmune?

Does the media refer more to IVVD or ALT?

Is IVVD or ALT more profitable?

Which has higher earnings and valuation, IVVD or ALT?

Which has more volatility & risk, IVVD or ALT?

Do analysts recommend IVVD or ALT?

Do institutionals and insiders believe in IVVD or ALT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD vs. The Competition

Invivyd Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools